Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250020/S002

Belotero Volume (+) Lidocaine Dermal Filler

Merz North America, Inc. · Decision date Jun 25, 2026

FDA DECISIONP250020/S002

What did the FDA decide?

FDA records P250020/S002 as a supplement to PMA P250020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 25, 2026.

FDA approval order statement

qualification of an alternative grade of disodium phosphate (salt) used in preparation of Belotero Volume (+) Lidocaine Dermal Filler
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Jun 25, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P250020/S002
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
OK30
Decision date
Jun 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P250020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250020 · Original PMA

    Belotero Volume (+) Lidocaine

  2. P250020/S002 received

    Application receipt date recorded by FDA.

  3. P250020/S001 · Related supplement

    Belotero Volume (+) Lidocaine

  4. P250020/S003 · Related supplement

    Belotero Volume (+) Lidocaine

  5. P250020/S002 · FDA decision

    30-Day Notice

  6. P250020/S005 · Related supplement

    Belotero Volume (+) Lidocaine Dermal Filler

  7. P250020/S004 · Related supplement

    Belotero Volume (+) Lidocaine

Timeline entries are records held by MedtechLedger for P250020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250020

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA approvalMay 19, 2026FDA
Merz North America, Inc.PMA supplementJun 17, 2026FDA
Merz North America, Inc.PMA supplementJun 23, 2026FDA
Merz North America, Inc.PMA supplementSep 10, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6501 Six Forks Rd., Raleigh, NC, 27615

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records